All In Biotech

Free tool

FAERS Monitor: Lunsumio Velo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761263 or its brand name (Lunsumio Velo, Mosunetuzumab-Axgb). Reports on generic versions are filed under their own applications.

Reports

1,107

Serious

950

86% of reports

Hospitalization

467

Death reported

156

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • cytokine release syndrome299
  • disease progression134
  • neutropenia96
  • off label use77
  • pyrexia72
  • covid-1969
  • death52
  • pneumonia51
  • malignant neoplasm progression46
  • rash44
  • covid-19 pneumonia41
  • thrombocytopenia34
  • disorientation32
  • neurological symptom31
  • vasogenic cerebral oedema31

Reports by year received

View as table
YearReports
20184
20195
202016
202152
202283
2023335
2024104
2025195
2026313

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,052 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vasogenic cerebral oedemaSignal31855.7600.024,514
cytokine release syndromeSignal299287.5260.783,887
neurological symptomSignal31103.773.23,034
covid-19 pneumoniaSignal4166.249.02,561
disease progressionSignal13421.518.42,616
disorientationSignal3215.410.9416
neutropeniaSignal9613.411.11,098
malignant neoplasm progressionSignal468.56.4300
covid-19Signal697.55.9384
thrombocytopeniaSignal345.84.2130
pyrexiaSignal724.03.2159
pneumoniaSignal513.02.367
rash441.91.419
off label use771.71.321
death521.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.